Procter & Gamble is reportedly about to acquire Thorne, an American wellness and health products maker, from L Catterton, the investment fund backed by LVMH, for an amount of $3.8 billion in cash, according to Premium Beauty News.
Founded in 1984, Thorne offers consumers and athletes a full range of dietary supplements. The deal would add to P&G's portfolio, which already includes the brands New Chapter, Metamucil and Align Probiotic.
« Il s'agit d'une étape importante pour l'activité de santé grand public (Personal Health Care) de P&G », affirme Paul Gama, CEO de P&G Health Care. He adds that consumer interest in self-care, prevention, wellness and personalised health continues to grow, and that Thorne would strengthen the group's position in premium wellness.
On Thorne's side, Colin Watts, CEO of the company, highlights the trust the brand has built up. « Depuis plus de 40 ans, Thorne a su gagner la confiance des professionnels de santé, des consommateurs et de ses partenaires en plaçant la science, la qualité et l'humain au cœur de chacune de nos décisions », explique-t-il.
Financial context
The announcement comes after P&G indicated last week that it expects a slowdown in its annual sales growth rate, despite the solid performance of its beauty and wellness division. According to WWD, P&G shares rose 1.5% following the announcement, reaching $147.20.
The transaction is expected to close during the course of the year, subject to customary closing conditions and regulatory approvals.
